Trabeculectomy in patients with diabetes: subconjunctival Mitomycin C with or without intravitreal bevacizumab
British Journal of Ophthalmology Dec 20, 2020
Nilforushan N, Es'haghi A, Miraftabi A, et al. - Researchers conducted the study for assessing the success of Mitomycin C (MMC) augmented trabeculectomy with or without intravitreal bevacizumab in patients with diabetes without neovascular glaucoma. For this analysis, 56 patients with diabetes who required trabeculectomy were randomised to either combination of 2.5 mg intravitreal bevacizumab and subconjunctival MMC (group A, 28 eyes) or subconjunctival MMC alone (group B, 28 eyes). Intraocular pressure (IOP), number of antiglaucoma medications, bleb morphology and success probability were the main outcome measures. Combined administration of intravitreal bevacizumab and subconjunctival MMC resulted in lower IOP and number of antiglaucoma medication in patients with diabetes with primary trabeculectomy compared with subconjunctival MMC alone.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries